Last reviewed · How we verify
Gamolenic (GAMOLENIC ACID)
At a glance
| Generic name | GAMOLENIC ACID |
|---|---|
| Drug class | gamolenic acid |
| Target | Free fatty acid receptor 1, Peroxisome proliferator-activated receptor delta, 3-oxo-5-alpha-steroid 4-dehydrogenase 2 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Role of 12-lipoxygenase in Platelet Reactivity and Type 2 Diabetes Mellitus (EARLY_PHASE1)
- Effectiveness of Evening Primrose Oil for Induction of Labor (EARLY_PHASE1)
- Anti-Inflammatory Diet in BRC Patients on Aromatase Inhibitors (NA)
- Gamma-linolenic Acid Supplementation Study (NA)
- Effect of Lavender Versus Primrose Oil on Menopause Symptom (NA)
- Fish Oil and EPO in Breast Cancer (NA)
- Oral DS107 in Moderate to Severe Atopic Dermatitis (PHASE2)
- A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gamolenic CI brief — competitive landscape report
- Gamolenic updates RSS · CI watch RSS